Recurrent Melanoma Completed Phase 3 Trials for Dacarbazine (DB00851)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00003647Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV MelanomaTreatment
NCT01359956Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant MelanomaTreatment